表紙
市場調査レポート

BerGenBio AS の製品パイプライン分析

BerGenBio AS - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 293959
出版日 ページ情報 英文 27 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
BerGenBio AS の製品パイプライン分析 BerGenBio AS - Product Pipeline Review - 2015
出版日: 2015年05月13日 ページ情報: 英文 27 Pages
概要

BerGenBio AS はノルウェーに本社をおくバイオテクノロジー企業で、バイオテクノロジー産業や医薬品産業向けに研究開発の受託を行っています。

当レポートでは、BerGenBio AS における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

BerGenBio AS の基本情報

  • BerGenBio AS の概要
  • 主要情報
  • 企業情報

BerGenBio AS :R&Dの概要

  • 主な治療範囲

BerGenBio AS :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

BerGenBio AS :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

BerGenBio AS :薬剤プロファイル

  • BGB-324
  • BGB-001
  • BGB-002
  • BGB-003
  • BGB-109

BerGenBio AS :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

BerGenBio AS :最新のパイプライン情報

BerGenBio AS :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07076CDB

Summary

Global Markets Direct's, 'BerGenBio AS - Product Pipeline Review - 2015', provides an overview of the BerGenBio AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BerGenBio AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BerGenBio AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BerGenBio AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BerGenBio AS's pipeline products

Reasons to buy

  • Evaluate BerGenBio AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BerGenBio AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BerGenBio AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BerGenBio AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BerGenBio AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BerGenBio AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BerGenBio AS Snapshot
    • BerGenBio AS Overview
    • Key Information
    • Key Facts
  • BerGenBio AS - Research and Development Overview
    • Key Therapeutic Areas
  • BerGenBio AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • BerGenBio AS - Pipeline Products Glance
    • BerGenBio AS - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • BerGenBio AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • BerGenBio AS - Drug Profiles
    • BGB-324
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Inhibit AXL Kinase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 3 to Inhibit AXL Kinase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-1 to Inhibit AXl Kinase for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BGB002 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BerGenBio AS - Pipeline Analysis
    • BerGenBio AS - Pipeline Products by Target
    • BerGenBio AS - Pipeline Products by Route of Administration
    • BerGenBio AS - Pipeline Products by Molecule Type
    • BerGenBio AS - Pipeline Products by Mechanism of Action
  • BerGenBio AS - Recent Pipeline Updates
  • BerGenBio AS - Dormant Projects
  • BerGenBio AS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BerGenBio AS, Key Information
  • BerGenBio AS, Key Facts
  • BerGenBio AS - Pipeline by Indication, 2015
  • BerGenBio AS - Pipeline by Stage of Development, 2015
  • BerGenBio AS - Monotherapy Products in Pipeline, 2015
  • BerGenBio AS - Phase I, 2015
  • BerGenBio AS - Preclinical, 2015
  • BerGenBio AS - Discovery, 2015
  • BerGenBio AS - Pipeline by Target, 2015
  • BerGenBio AS - Pipeline by Route of Administration, 2015
  • BerGenBio AS - Pipeline by Molecule Type, 2015
  • BerGenBio AS - Pipeline Products by Mechanism of Action, 2015
  • BerGenBio AS - Recent Pipeline Updates, 2015
  • BerGenBio AS - Dormant Developmental Projects,2015

List of Figures

  • BerGenBio AS - Pipeline by Top 10 Indication, 2015
  • BerGenBio AS - Pipeline by Stage of Development, 2015
  • BerGenBio AS - Monotherapy Products in Pipeline, 2015
  • BerGenBio AS - Pipeline by Top 10 Target, 2015
  • BerGenBio AS - Pipeline by Top 10 Molecule Type, 2015
  • BerGenBio AS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top